iRhythm Q1 Revenue Jumps 25.7% to $199.4M; Full-Year Guidance Upgraded
IRTC•iRhythm reported Q1 2026 revenue of $199.4 million, up 25.7% year-over-year, with gross margin rising 210 basis points to 70.9% and net loss narrowing to $13.9 million. It raised full-year revenue guidance to $875–885 million and adjusted EBITDA margin to 12–13% on stronger volume-led growth and operational leverage.
1. Strong Q1 Financial Performance
iRhythm recorded Q1 2026 revenue of $199.4 million, up 25.7% year-over-year, driven by higher Zio service volumes. Gross profit rose 29.4% to $141.4 million, with a 210-basis-point increase in gross margin to 70.9%; net loss narrowed to $13.9 million and adjusted EBITDA reached $14.1 million.
2. Full-Year 2026 Guidance Raised
The company increased its 2026 revenue outlook to $875–885 million and adjusted EBITDA margin to 12–13%, citing sustained volume growth and operational efficiencies expected to support further margin expansion and profitability improvements.
3. Operational and Strategic Initiatives
Momentum continued across cardiology, primary care, innovative partnerships, and international markets, supported by presentations of new Zio portfolio data and the launch of a digital education platform. Investments in AI-enabled capabilities aim to drive earlier detection and lower total cardiac care costs.
